Boron neutron capture therapy for malignant glioma in the combination of BSH and BPA

点击翻译按钮获取中文摘要

The present report evaluates as a coperative study in Europe and Japan the pharmacokinetics and boron uptake of sodium borocaptate (BSH) and p-dihydroxyboryl phenylalanine (BPA), which has been introduced clinically as a boron carrier for boron neutron capture therapy (BNCT) in patients with glioblastoma.First, we evaluated the BSH pharmacokinetics and boron uptake clmically in 56 patients with glioblastoma after BSH intravenous infusion. For BNCT with BSH after intravenous infusion, The pharmacokinetics and boron uptake study confirm that the planned neutron irradiation after intravenous BSH infusion appears to be optimal around 12-19 hours after the infusion.Second, we analyzed the subcellular biodistrubution of BSH in a rat glioma model using immunohistichemical approach in a C6 glioma model.The Wister rats were used for this experiment. An intracerebral injection of 5.0 x 106 C6 glioma cells was introduced into the region of cerebral hemishere. Fifty mg 10B/kg BSH was infused to the rats intravenously two weeks after implantation. Host rats were divided into six groups according to the sampling time: 1hr, 4hrs, 8hrs, 16hrs, 24hrs, 48hrs. After the start of BSH infusion, Immunohistochemical study was carried out using anti-BSH antibody. Boron was already found in a whole cell one hour after BSH infusion, and then seemed to collect in cell nuclei around eight to 16 hours after infusion. It was recognized in tumor cells still 48 hours after infusion.In the case of BPA, it has been reported that neutron radiation is optimal after 1 hour after BPA infusion. This study lead that BSH is infused 12-15 hours before, and BPA is infused 1 hour before neutron irradiation to achieve the optimal clinical results in the combination of BSH and BPA.